In September, FTC filed a complaint against USAP and its private equity founder Welsh Carson. Along with other claims, FTC alleges that USAP engaged in monopolization through serial acquisitions of anesthesia practices, emphasizing the role of USAP's PE backer. We'll discuss the implications of FTC's unusual claims for continued agency interest in the role of private equity firms in healthcare.
Sponsored by the Antitrust Law Section Pricing Conduct and Unilateral Conduct Committees.
The content of this program does not meet requirements for continuing legal education (CLE) accreditation. You will not receive CLE credit for participating.
